Claims for Patent: 10,271,876

Summary for Patent: 10,271,876

Title:	Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
Abstract:	A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient\'s autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Inventor(s):	Feskov; Alexander (Kharkov, UA), Feskova; Irina (Kharkov, UA), Zhylkova; Ievgeniia (Kharkov, UA), Zhilkov; Stanislav (Philadelphia, PA)
Assignee:	MEZADATA MEDICAL IP HOLDING LLC (Dover, DE)
Application Number:	13/655,257
Patent Claims:	1. A method of in vitro fertilization for a female patient, the method comprising: (a) introducing into the uterus an effective amount of a composition comprising peripheral blood mononuclear cells, and (b) transferring at least one embryo into the uterus of the patient, wherein the at least one embryo is derived from at least one oocyte retrieved from the patient at least two months prior to the transferring of the at least one embryo, wherein: prior to introducing the composition comprising peripheral blood mononuclear cells into the uterus, at least a portion of the peripheral blood mononuclear cells were cultured in the presence of human chorionic gonadotropin; the peripheral blood mononuclear cells are derived from blood collected from the patient at a first time between (i) transferring the at least one embryo into the uterus of the patient and (ii) three days prior to transferring the at least one embryo into the uterus of the patient; and the method results in an increase in the probability of implantation of the at least one embryo in the uterus with successful inception of pregnancy when compared to in vitro fertilization methods lacking at least one of (a) and (b). 2. The method of claim 1, wherein the at least two month period of time between the retrieval of the at least one oocyte from the patient and the transferring of the at least one embryo is an amount of time sufficient to decrease the risk of autoimmune response of the patient. 3. The method of claim 1, wherein the at least two month period of time between the retrieval of the at least one oocyte from the patient and the transferring of the at least one embryo corresponds to at least two menstrual cycles or two cycles of ovulation of the patient. 4. The method of claim 1, wherein the at least one embryo is transferred to the uterus within an embryo transfer medium and the embryo transfer medium comprises an inception-promoting agent. 5. The method of claim 4, wherein the patient is a human, the inception-promoting agent is soluble human leukocyte antigen G (sHLA-G) and the concentration of the sHLA-G in the embryo transfer medium is in the range 0.175-0.350 OD, where OD means the optical density measured at a wavelength in the range of 400 to 450 nm. 6. The method of claim 5, further comprising culturing the at least one embryo in said embryo transfer medium for a period of time in the range of 5 min to 20 min immediately prior to transferring the at least one embryo into the uterus. 7. The method of claim 1, wherein the patient is of human, murine, or livestock animal origin. 8. The method of claim 1, wherein the at least one oocyte is retrieved from the patient two to twelve months prior to the transferring of the at least one embryo. 9. The method of claim 8, wherein during the two to twelve months prior to the transferring of the at least one embryo, controlled ovarian stimulation was not performed on the patient. 10. The method of claim 1, wherein the at least one oocyte is retrieved from the patient three to twelve months prior to the transferring of the at least one embryo. 11. The method of claim 1, wherein during the at least two months prior to the transferring of the at least one embryo, controlled ovarian stimulation was not performed on the patient. 12. The method of claim 1, wherein: a first portion of the peripheral blood mononuclear cells is derived from the blood collected from the patient at the first time between (i) transferring the at least one embryo into the uterus of the patient and (ii) three days prior to transferring the at least one embryo into the uterus of the patient, a second portion of the peripheral blood mononuclear cells is derived from blood collected from the patient at a second time between (i) transferring the at least one embryo into the uterus of the patient and (ii) three days prior to transferring the at least one embryo into the uterus of the patient, and the second time is after the first time. 13. The method of claim 12, wherein the first portion of the peripheral blood mononuclear cells is obtained by the culturing, in the presence of human chorionic gonadotropin, of the peripheral blood mononuclear cells from the blood collected from the patient at the first time. 14. A method of in vitro fertilization for a female patient, the method comprising: (a) initiating ovulation in the patient to obtain at least one oocyte, (b) obtaining peripheral blood mononuclear cells from the patient (PBMCs), (c) fertilizing the at least one oocyte obtained in (a) with spermatozoa to create at least one embryo, (d) introducing the patient's PBMCs into the uterus of the patient at least two months after (a), and (e) introducing the at least one embryo of (c) into the uterus of the female patient after (d) to effectuate implantation of the at least one embryo in the uterus, wherein: at least a portion of the PBMCs obtained from the patient in (b) were cultured in the presence of human chorionic gonadotropin before introducing the PBMCs into the uterus of the patient in (d): and the obtaining of the PBMCs from the patient in (b) was performed at most three days prior to introducing the at least one embryo into the uterus of the patient in (e). 15. The method of claim 14, wherein the at least one embryo is introduced into the uterus of said patient 20-24 hours after (d). 16. The method of claim 14, wherein in (d) the patient's PBMCs are introduced into the uterus of the patient two to twelve months after (a). 17. The method of claim 16, wherein during the two to twelve months between (a) and (d), controlled ovarian stimulation was not performed on the patient. 18. The method of claim 14, wherein in (d) the patient's PBMCs are introduced into the uterus of the patient three to twelve months after (a). 19. The method of claim 14, wherein during the at least two months between (a) and (d), controlled ovarian stimulation was not performed on the patient. 20. The method of claim 14, wherein: a first portion of the PBMCs introduced into the uterus of the patient in (d) is derived from blood collected from the patient at a first time between (i) introducing the at least one embryo into the uterus of the patient in (e) and (ii) three days prior to introducing the at least one embryo into the uterus of the patient in (e), a second portion of the PBMCs introduced into the uterus of the patient in (d) is derived from blood collected from the patient at a second time between (i) introducing the at least one embryo into the uterus of the patient in (e) and (ii) three days prior to introducing the at least one embryo into the uterus of the patient in (e), and the second time is after the first time. 21. The method of claim 20, wherein the first portion of the PBMCs is obtained by the culturing, in the presence of human chorionic gonadotropin, of the PBMCs from the blood collected from the patient at the first time.

Details for Patent 10,271,876

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2032-10-18
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2032-10-18
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2032-10-18
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2032-10-18
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974		2032-10-18
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973		2032-10-18